Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced that Dr. Gregory Berk has joined the company as Chief Medical Officer (CMO). Dr. Berk is a seasoned clinical researcher with over three decades of experience in developing innovative drugs. He will lead the clinical teams in the U.S. and China, and oversee the Phase I/II clinical trials in both regions.
Dr. Berk has previously served as SVP or CMO at several U.S.-based biotech/biopharma companies, such as Abraxis BioScience, Intellikine, BIND BioSciences, Sideris Pharmaceuticals, and GT Biopharma. His extensive clinical trial expertise and industry connections will enable Allorion to advance from preclinical research to clinical development, creating new therapies to address major unmet medical needs and generate value for the company. Dr. Berk earned his B.S. in Biochemistry from Tulane University and M.D. from Case Western Reserve University School of Medicine. He completed his residency training at Joan & Sanford I. Weill Medical College of Cornell University.